Advanced search
Publication Cover
Current Opinion on Therapeutic Patents Volume 2, 1992 - Issue 8
Journal homepage
10
Views
5
CrossRef citations to date
0
Altmetric
CNS Agents

Overview: Excitatory Amino Acid Antagonists

Michael Rowley Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
&
Paul D Leeson Merck Sharp and Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex, CM20 2QR, UK
Pages 1201-1221 | Published online: 02 Mar 2011

References to Primary Literature

  • Marmo, B L-Glutamic acid as a neurotransmitter in the CNS. Medicinal Res. Rev. 1988 20 925–929.
  • Meldrum, B Garthwaite, J Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol. Sci. 1990 11 379–387.
  • Wolfe, PA An overview of the epidemiology of stroke. Stroke 1990 21 Suppl II 4–6.
  • Watkins, JC Krogsgaard-Larsen, P Honoré, T Structure-activity relationships in the development of excitatory amino acid receptor agonists and competitive antagonists. Trends Pharmacol. Sci. 1990 11 25–33.
  • Lodge, D Johnson, KM Non-competitive excitatory amino acid antagonists. Trends Pharmacol. Sci. 1990 11 81–86.
  • Johnson, JW Ascher, P Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 1987 325 529–531.
  • Ransom, RW Stec, NL Cooperative modulation of [3H]-MK-801 binding to the N-methyl-D-asparate receptor-ion channel complex by L-glutamate, glycine, and poly-amines. J. Neurochem. 1988 51 830–836.
  • Scatton, B Frost, J George, P Carter, C Benavides, J Present developments in NMDA receptor antagonists in cerebral ischaemia. Curr. Opin. Thera. Patents 1991 1 523–545.
  • Meldrum, B Protection against ischaemic neuronal damage by drugs acting on excitatory neurotransmission. Cerebrovascular and Brain Metabolism Reviews 1990 2 27–57.
  • Compton, RP Hood, WF Monahan, JB Determination of the pharmacokinetics of 2-amino-7-phosphonoheptanoate in rat plasma and cerebrospinal fluid. Neurosci. Lett. 1988 84 339–344.
  • Whitten, JP Baron, BM Muench, D Miller, F White, HS McDonald, IA (R)-4-Oxo-5-phosphononovaline: A new competitive glutamate antagonist at the NMDA receptor complex. J. Med. Chem. 1990 33 2961–2963.
  • Bigge, CF Wu, J-P Drummeond, JT Coughenour, LL Hanchin, CM Excitatory amino acids: 6-Phosphonomethyltetrahydro-4-pyrimidinecarboxylic acids and their acyclic analogues are competitive N-methyl-D-aspartic acid receptor antagonists. Bioorg. Med. Chem. Lett. 1992 2 207–212.
  • Wong, EHF Kemp, JA Priestley, T Knight, AR Woodruff, GN Iversen, LL The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc. Natl. Acad. Sci. USA 1986 83 7104–7108.
  • Thompson, WJ Anderson, PS Britcher, SF Lyle, TA Thies, JE Magill, CA Varga, SL Schwering, JE Lyle, PA Christy, ME Evans, BE Colton, CD Holloway, MK Springer, JD Hirshfield, JM Ball, RG Amato, JS Larsen, RD Wong, EHF Kemp, JA Tricklebank, MD Singh, L Oles, RJ Priestley, T Marshall, GR Knight, AR Middlemiss, DN Woodruff, GN Iversen, LL Synthesis and pharmacological evaluation of a series of dibenzo[a,d]cycloalkenimines as N-methyl-D-aspartate antagonists. J. Med. Chem. 1990 33 789–808.
  • Leeson, PD Carling, RW James, K Smith, JD Moore, KW Wong, EHF Baker, R Role of hydrogen bonding in ligand interaction with the N-methyl-D-aspartate receptor ion channel. J. Med. Chem. 1990 33 1296–1305.
  • Bormann, J Memantine is a potent blocker of N-methyl-D-asparate (NMDA) receptor channels. Eur. J. Pharmacol. 1989 166 591–592.
  • Griffith, R Murray, R Napier, J Palmer, G Blosser, G Harris, E Ordy, M Ray, R Bialobok, P Borelli, A Cregan, E Wengenack, T Preclinical neuroprotective profile of remacemide, a prodrug NMDA antagonist American Chemical Society 201st National Meeting Atlanta, Georgia 1991.
  • Garske, GE Palmer, GC Napier, JJ Griffith, RC Freedman, LR Harris, EW Ray, Y McCready, SA Blosser, JC Woodhead, JH White, HS Swinyard, EA Preclinical profile of the anticonvulsant Remacemide and its enantiomers in the rat. Epilepsy Res. 1991 9 161–174.
  • Childers, WE Cerebral anti-ischaemic agents: Recent advances, June through December, 1991. Curr. Opin. Thera. Patents 1992 2 146–162.
  • Kemp, JA Grimwood, S Foster, AC Characterisation of the antagonism of excitatory amino acid receptors in rat cortex by kynurenic acid. Br. J. Pharmacol. 1987 91 314P.
  • Kemp, JA Foster, AC Leeson, PD Priestley, T Tridgett, R Iversen, LL Woodruff, GN 7-Chlorokynurenic acid is a selective antagonist at the glycine modulatory site of the N-methyl-D-aspartate receptor complex. Proc. Natl. Acad. Sci. USA 1988 85 6547–6550.
  • Leeson, PD Baker, R Carling, RW Curtis, NR Moore, KW Williams, BJ Foster, AC Donald, AE Kemp, JA Marshall, GR Kynurenic acid derivatives. Structure-activity relationships for excitatory amino acid antagonism and identification of potent and selective antagonists at the glycine site on the N-methyl-D-aspartate receptor. J. Med. Chem. 1991 34 1243–1252.
  • Harrison, BL Baron, BM Cousino, DM McDonald, IA 4-[(Carboxymethyl)oxy]- and 4-[(carboxymethyl)amino]-5,7-dichloroquinoline-2-carboxylic acid: New antagonists of the strychnine-insensitive glycine binding site on the N-methyl-D-aspartate receptor complex. J. Med. Chem. 1990 33 3130–3132.
  • Grimwood, S Moseley, AM Carling, RW Leeson, PD Foster, AC Characterisation of the binding of [3H]-L-689,560, an antagonist for the glycine site of the N-methyl-D-aspartate receptor, to rat brain membranes. Mol. Pharmacol. 1992 41 923–930.
  • Salituro, FG Harrison, BL Baron, BM Nyce, PL Stewart, KT McDonald, IA 3-(2-Carboxyindol-3-yl)propionic acid deriatives: Antagonists of the strychnine insensitive glycine receptor associated with the N-methyl-D-asparate receptor complex. J. Med. Chem. 1990 33 2944–2946.
  • Salituro, FG Tomlinson, RC Baron, BM Demeter, DA Weinraub, HJR McDonald, IA Design, synthesis and molecular modelling of 3-acylamino-2-carboxyindole NMDA receptor glycine-site antagonists. Bioorg. Med. Chem. Lett. 1991 1 455–460.
  • Gray, NM Dappen, MS Cheng, BK Cordi, AA Biesterfield, JP Hood, WF Monahan, JB Novel indole 2-carboxylates as ligands for the strychnine insensitive N-methyl-D-aspartate-linked glycine receptor. J. Med. Chem. 1991 34 1283–1292.
  • Singh, L Donald, AE Foster, AC Hutson, PH Iversen, LL Iversen, SD Kemp, JA Leeson, PD Marshall, JA Oles, RJ Priestley, T Thorn, L Tricklebank, MD Vass, CA Williams, BJ Enantiomers of HA-966 (3-amino-1-hydroxypyrrolid-2-one) exhibit distinct central nervous system effects: (+)-HA-966 is a selective glycine/N-methyl-D-aspartate receptor antagonist, but (–)-HA-966 is a potent γ-butyrolactone-like sedative. Proc. Natl. Acad. Sci. USA 1990 87 347–351.
  • Randle, JCR Guet, T Bibichon, C Moreau, C Curuchet, P Lambolez, B de Carvalho, LP Cordi, A Lepagnol, JM Quinoxaline derivatives: Structure-activity relationships and physiological implications of inhibition of N-methyl-D-aspartate and non-N-methyl-D-asparate receptor-mediated currents and synaptic potentials. Mol. Pharmacol. 1992 41 337–345.
  • Erez, U Frenk, H Goldberg, O Cohen, A Teichberg, VI Anticonvulsant properties of 3-hydroxy-2-quinoxalinecarboxylic acid, a newly found antagonist of excitatory amino acids. Eur. J. Pharmacol. 1985 110 31–39.
  • Watson, GB Lanthorn, TH Pharmacological characteristics of cyclic homologues of glycine at the N-methyl-D-asparatate recetpro-associated glycine site. Neuropharmacology 1990 29 727–730.
  • Smith, ECR Synthesis and excitatory amino acid pharmacology of a series of heterocyclic fused quinoxalinones and quinazolinones. Soc. Neurosci. Abst. 1991 17 108.6.
  • Jackson, PF Davenport, TW Resch, JF Lehr, GS Pullan, LM Tricyclic quinoxalines as ligands for the strychnine insensitive glycine site. Bioorg. Med. Chem. Lett. 1991 1 751–756.
  • Carter, C Rivy, J-P Scatton, B Ifenprodil and SL 82.0715 are antagonists at the polyamine site of the N-methyl-D-aspartate (NMDA) receptor. Eur. J. Pharmacol. 1989 164 611–612.
  • Chenard, BL Shalaby, IA Koe, BK Ronau, RT Butler, TW Prochniak, MA Schmidt, AW Fox, CB Separation of α1 adrenergic and N-methyl-D-aspartate antagonist activity in a series of ifenprodil compounds. J. Med. Chem. 1991 34 3085–3090.
  • Ouardouz, M Durand, J GYKI 52466 antagonizes glutamate responses but not NMDA and kainate. Neurosci. Lett. 1991 125 5–8.
  • Bersenyi, P Tarnawa, I Farkas, S Andràsi, F Pharmacology of a new centrally acting muscle relaxant. Pharmacol. Res. Comm. 1986 20 Suppl 1 139.
  • Bettler, B Egebjerg, J Sharma, G Pecht, G Hermans-Borgmeyer, I Moll, C Stevens, CF Heinemann, S Cloning of a putative glutamate receptor: A low affinity kainatebinding subunit. Neuron 1992 8 257–265.
  • Hume, RI Dingledine, R Heinemann, SF Identification of a site in glutamate receptor subunits that controls calcium permeability. Science 1991 253 1028–1031.
  • Sun, W Ferrer-Montiel, AV Schinder, AJ McPherson, JP Evans, GA Montal, M Molecular cloning, chromosomal mapping, and functional expression of human brain glutamate receptors. Proc. Natl. Acad. Sci. USA 1992 89 1443–1447.
  • Moriyoshi, K Masu, M Ishii, T Shigemoto, R Mizuno, N Nakanishi, S Molecular cloning and characterization of the rat NMDA receptor. Nature 1991 354 31–37.
  • Masu, M Tanabe, Y Tsuchida, K Shigemoto, R Nakanishi, S Sequence and expression of a metabotropic glutamate receptor. Nature 1991 349 760–765.
  • Yamazaki, M Mori, H Araki, K Mori, KJ Mishina, M Cloning, expression and modulation of a mouse NMDA receptor subunit. FEBS Utters 1992 300 39–45.
  • Hogan, MJ Gjedde, A Hakim, AM In vivo distribution of CGS-19755 within brain in a model of focal cerebral ischaemia. J. Neurochem. 1992 58 186–191.
  • Smith, SE Dürmüller, N Meldrum, BS The non-N-methyl-D-aspartate receptor antagonists, GYKI 452466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 1991 201 179–183.
  • Mizoule, J Meldrum, B Mazadier, M Corucher, M Oilat, C Uzan, A Legrand, J-J Gueremy, C Le Fur, G 2-Amino-6-trifluoromethoxy benzothiazole, a possible antagonist of excitatory amino acid neurotransmission-1. Neuropharmacology 1985 24 767–773.
  • Tricklebank, MD Singh, L Oles, RJ Preston, C Iversen, SD The behavioural effects of MK-801: A comparison with antagonists acting non-comeptitively and competitively at the NMDA receptor. Eur. J. Pharmacol. 1989 167 127–135.
  • Ferkany, JW Borosky, SA Clissold, DB Pontecorvo, MJ Dextromethorphan inhibits NMDA-induced convulsions. Eur. J. Pharmacol. 151 151–154.
  • Rogawski, MA Yamaguchi, S-I Jones, SM Rice, KC Thurkauf, A Monn, JA Anticonvulsant activity of the low affinity N-methyl-D-aspartate antagonist (±)-5-aminocarbonyl-10,11-dihydro-5H-dibenzo[a,d]cyclo-hepten-5,10-imine (ADCI): Comparison with the structural analogues Dizocilpine (MK-801) and Carbamezepine. J. Pharmacol. Exp. Ther. 1991 259 30–37.
  • Bennett, DA Bernard, PS Amrick, CL Wilson, DE Liebman, JM Hutchison, AJ Behavioural pharmacological profile of CGS 19755, a competitive antagonist at N-methyl-D-aspartate receptors. J. Pharmacol. Exp. Ther. 1989 250 454–460.
  • Ornstein, PL Arnold, MB Augenstein, NK Schoep, DD Leander, JD Lodge, D The discovery of LY 274614 and LY 233536 and their characterization as selective and competitive NMDA antagonist. Soc. Neurosci. Abstr. 1990 16 856.3.
  • Foster, AC Kemp, JA Tricklebank, MD Leeson, PD Carling, RW Williams, BJ Grimwood, S Donald, AE Priestley, T Marshall, GR Saywell, K Gill, R Selective antagonists for the glycine site of the N-methyl-D-aspartate receptor. Mol. Neuropharmacol. 1992 2 97–102.
  • Perrault, G Morel, E Sanger, DJ Zivkovic, B Comparison of the pharmacological profiles of four NMDA antagonists, Ifenprodil, SL 82.0715, MK-801 and CPP, in mice. Br. J. Pharmacol. 1989 97 580P.
  • Chapman, AG Graham, JL Patel, S Meldrum, BS Anti-convulsant activity of two orally active competitive N-methyl-D-aspartate antagonists, CGP 37849 and CGP 38551, against sound-induced seizures in DBA/2 mice and photically induced myoclonus in Papio papio. Epilepsia 1991 32 578–587.
  • Chapman, AG Graham, J Meldrum, BS Potent oral anticonvulsant action of CPP and CPPEene in DBA/2 mice. Eur. J. Pharmacol. 1990 178 97–99.
  • Chapman, AG Anticonvulsant activity of excitatory amino acid antagonists Frontiers in Excitatory Amino Acid Research Cavalheiro, EA, Lehmann, J, Turski, L Alan R Liss New York 1988.
  • Smith, SE Meldrum, BS The glycine-site NMDA receptor antagonist, R-(+)-cis-β-me-thyl-3-amino-1-hydroxypyrrolid-2-one, L-687,414 is anticonvulsant in baboons. Eur. J. Pharmacol. 1992 211 109–111.
  • Gill, R Brazell, C Woodruff, GN Kemp, JA The neuroprotective action of dizocilpine (MK-801) in the rat middle cerebral artery model of focal ischaemia. Br. J. Pharmacol. 1991 103 2030–2036.
  • Kent, TA Eisenberg, H Quast, M Anderson, A Hillman, G Campbell, G Dextrorphan reduces infarct volume after middle cerebral occlusion in rats: A magnetic resonance imaging and histopathology study. J. Cereb. Blood Flow Metab. 1989 9 Suppl 1 S153.
  • Park, CK McCulloch, J McBurney, R Kang, JK Choi, CR Respiratory depression attenuates the anti-ischaemic effects of the NMDA ion channel blocker CNS 1102 J. Cereb. Blood Flow Metab. 1991 11 Suppl 2 S220.
  • Bullock, R Graham, DI Chen, M-H Lowe, D McCulloch, J Focal cerebral ischaemia in the cat: Pretreatment with a competitive NMDA receptor antagonist, D-CPPene. J. Cereb. Blood Flow Metab. 1990 10 668–674.
  • Graham, DI Chen, M-H Bullock, R Lowe, D McCulloch, J The competitive NMDA antagonist D-CPPene reduces focal ischaemia damage: Pretreatment dose dependency and postischaemia treatment efficacy J. Cereb. Blood Flow Metab. 1991 11 Suppl 2 S308.
  • Sauer, D Massieu, L Allegrini, PR Fagg, G Comparative neuroprotective effects of competitive and non-competitive NMDA receptor antagonists in the rat. J. Cereb. Blood Flow Metab. 1991 11 Suppl 2 S298.
  • Simon, R Shiraishi, K N-Methyl-D-aspartate antagonist reduces stroke size and regional glucose metabolism. Ann. Neurol. 1990 27 606–611.
  • Gill, R Lodge, D The neuroprotective effects of novel competitive N-methyl-D-asparatate (NMDA) antagonists in a rat focal ischaemia model Poster at the Fidia Research Foundation Symposium, Excitatory Amino Acids 1992 Yosemite, California February 1992.
  • Gill, R Hargreaves, R Kemp, JA Neuroprotective effects of the glycine site antagonist (+)cis-4-methyl-HA-966 (L-687,414) in a rat focal ischaemia model. J. Cereb. Blood Flow Metab. 1991 11 Suppl 2 S304.
  • Gotti, B Duverger, D Bertin, J Carter, C Dupont, R Frost, J Gaudilliere, B MacKenzie, ET Rousseau, J Scatton, B Wick, A Ifenprodil and SL 82.0715 as cerebral anti-ischaemic agents. I. Evidence for efficacy in models of focal cerebral ischaemia. J. Pharmacol. Exp. Ther. 1988 247 1211–1221.
  • Gill, R Nordholm, L Lodge, D The neuroprotective actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline (NBQX) in a rat focal ischaemia model. Brain Research. 1992 580 35–43.
  • Smith, SE Meldrum, BS Neuroprotective effects of GYKI 52466 (1-(4-aminophenyl-4-methyl-7,8-methylen-dioxy-5H-2,3-benzodiazepine) after focal ischaemia in the rat. Br. J. Pharmacol. 1991 Proceedings Supplement 21P.
  • Nobbs, MS Inhibitors of glutamate release as neuroprotective agents. Lecture at the 6th SCI-RSC Medicinal Chemistry Symposium Cambridge, UK. 1991.
  • Fleischer, JE Tateishi, A Drummond, JC Scheller, MS Grafe, MR Zornow, MH Shearman, GT Shapiro, HM MK-801, an excitatory amino acid antagonist, does not improve neurological outcome following cardiac arrest in cats. J. Cereb. Blood Flow Metab. 1989 9 795–804.
  • Lanier, WL Perkins, WJ Karlsson, BR Milde, JH Scheithauer, BW Shearman, GT Michenfelder, JD The effects of Dizocilpine maleate (MK-801), an antagonist of the N-methyl-D-aspartate receptor, on neurological recovery and histopathology following complete cerebral ischaemia in primates. J. Cereb. Blood Flow Metab. 1990 10 252–261.
  • Nellgard, B Wieloch, T Postischaemic blockade of AMPA but not NMDA receptors mitigates neuronal damage following severe cerebral ischaemia. J. Cereb. Blood Flow Metab. 1992 12 2–11.
  • Le Peillat, E Arvin, B Moncada, C Meldrum, BS The non-NMDA antagonists, NBQX and GYKI 52455, protect against cortical and striatal loss following transient global ischaemia in the rat. Brain Res. 1992 571 115–120.
  • Sturgeon, RD Fessler, RG Meltzer, HY Behavioural rating scales for assessing phencyclidine-induced locomotor activity, stereotyped behaviour and ataxia in rats. Eur. J. Pharmacol. 1979 59 169.
  • Olney, JW Labruyere, J Price, MT Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989 244 1360–1362.
  • Allen, HL Iversen, LL Phencyclidine, Dizocilpine, and cerebrocortical neurones. Science 1990 247 221.
  • Olney, JW Labruyere, J Wang, G Wozniak, DF Price, MT Sesma, MA NMDA antagonist neurotoxicity: Mechanism and prevention. Science 1991 254 1515–1521.
  • Kurumaji, A Nehls, DG Park, CK McCulloch, J Effects of NMDA antagonists, MK-801 and CPP, upon local cerebral glucose use. Brain Res. 1989 469 268–284.
  • Lewis, SJ Barres, C Jacob, HJ Ohta, H Brady, MJ Cardiovascular effects of the N-methyl-D-aspartate receptor antagonist MK-801 in conscious rats. Hypertension 1989 13 759–765.
  • Collingridge, GL Singer, W Excitatory amino acids and synaptic plasticity. Trends Pharmacol. Sci. 1990 11 290–296.
  • Bischoff, C Tiedtke, PI Competitive and non-competitive NMDA receptor antagonists in spatial learning tasks. Eur. J. Pharmacol. 1992 213 269–273.
  • Macrae, IM Inglis, FM Vila, E Reid, JL McCulloch, J Central effects of competitive NMDA antagonist D-CPPene on brainstem cerebral glucose use and blood pressure control in the conscious rat. J. Cereb. Blood Flow Metab. 1991 11 Suppl 2 S309.
  • Saywell, K Singh, L Oles, RJ Vass, C Leeson, PD Williams, BJ Tricklebank, MD The anticonvulsant properties in the mouse of the glycine/NMDA receptor antagonist L-687,414. Br. J. Pharmacol. 1991 102 66P (Suppl)
  • Bourson, A Tricklebank, MD The discriminative stimulus properties of the glycine/NMDA receptor antagonist L-687,414. Fundam. Clin. Pharmacol. 1991 5 443.
  • Hargreaves, RJ Rigby, M Smith, D Foster, A Hurley, CJ Hill, RG L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, does not alter glucose metabolism or neuronal morphology at neuroprotective dose levels. J. Cereb. Blood Flow Metab. 1991 11 Suppl 2 S301.
  • Lipton, SA Models of neuronal injury in AIDS: Another role for the NMDA receptor?. Trends Neurosci. 1992 15 75–79.
  • Greenamyre, JT Young, AB Excitatory amino acids and Alzheimer's disease. Neurobiology of aging 1989 10 593–603.
  • Albin, RL Young, AB Penney, JB Handelin, B Balfour, R Anderson, KD Markel, DS Tourtelotte, WW Reiner, A Abnormalities of striatal neurons and NMDA receptors in presymptomatic Huntingdon's disease. New Engl. J. Med. 1990 322 1293–1298.
  • Plaitakis, A Constantakakis, E Smith, J The neuroexcitotoxic amino acids glutamate and aspartate are altered in the spinal cord and brain in Amyotrophic Lateral Sclerosis. Ann. Neurol. 1988 24 446–449.
  • Faden, AI Ellison, JA Noble, LJ Effects of competitive and non-competitive NMDA receptor antagonists in spinal cord injury. Eur. J. Pharmacol. 1990 175 165–174.
  • Klockgether, T Turski, L Honoré, T Zhang, A Gash, DM Kurlan, R Greenamyre, JT The AMPA receptor antagonists NBQX has antiparkinsonian effects in monoamine-depleted rats and MPTP-treated monkeys. Ann. Neurol. 1991 30 717–723.
  • Trujillo, KA Akil, H Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991 251 85.
  • Hutson, PH Bristow, LJ Thorn, L Tricklebank, MD R-(+)-HA-966, a glycine NMDA receptor antagonist, selectively blocks the activation of the mesolimbic dopamine system by amphetamine. Br. J. Pharmacol. 1991 103 2037–2044.
  • Sheardown, MJ The quinoxalinediones, a new series of potent and selective non-NMDA antagonists. Drugs Fut. 1989 14 667–674.
  • Trullas, R Skolnick, P Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur. J. Pharmacol. 1990 185 1–10.
  • Kehne, JH McCloskey, TC Baron, BM Chi, EM Harrison, BL Whitten, JP Palfreyman, MG NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations. Eur. J. Pharmacol 1991 193 283–292.
  • Lauritzen, M Sheardown, M Hansen, AJ The neuroprotective effect of the NMDA antagonist MK-801 and non-NMDA antagonist NBQX is not explained by an effect on anoxic depolarization, and only MK-801 inhibits spreading depression. J. Cereb. Blood Flow Metab. 1991 11 Suppl 2 S-222.
  • Näsström, J Karlsson, U Post, C Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice. Eur. J. Pharmacol. 1992 212 21–29.

References to Patent literature

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.